HC Wainwright Raises Atossa Therapeutics (NASDAQ:ATOS) Price Target to $7.00

Atossa Therapeutics (NASDAQ:ATOS) had its price target increased by HC Wainwright from $6.00 to $7.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.21) EPS.

A number of other equities research analysts also recently issued reports on the stock. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 8th. Ascendiant Capital Markets upped their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research report on Wednesday, September 11th.

Atossa Therapeutics Price Performance

NASDAQ:ATOS opened at $1.28 on Wednesday. The company has a market cap of $160.97 million, a price-to-earnings ratio of -5.82 and a beta of 1.23. Atossa Therapeutics has a 1 year low of $0.65 and a 1 year high of $2.31. The stock’s 50 day simple moving average is $1.44 and its two-hundred day simple moving average is $1.38.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after buying an additional 78,269 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Atossa Therapeutics by 1.6% in the third quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock worth $4,278,000 after buying an additional 44,762 shares during the last quarter. State Street Corp lifted its stake in shares of Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after buying an additional 69,180 shares during the period. Renaissance Technologies LLC grew its stake in Atossa Therapeutics by 11.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after purchasing an additional 164,540 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after purchasing an additional 399,041 shares during the last quarter. 12.74% of the stock is currently owned by institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.